Your session is about to expire
← Back to Search
LVGN3616 + LVGN6051 Combinations for Advanced Cancers
Study Summary
This trial is testing whether four different combinations of drugs can shrink tumors in seven different types of cancer. The drugs will be provided at no cost to patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA authorized LVGN3616 +LVGN6051+Nab-Paclitaxel for clinical use?
"The combination of LVGN3616, LVGN6051 and Nab-Paclitaxel have limited clinical data to support their safety and efficacy so they received a score of 1."
What medical condition is the combination of LVGN3616 + LVGN6051 + Nab-Paclitaxel typically utilized to treat?
"LVGN3616 + LVGN6051 + Nab-Paclitaxel is the conventional remedy for leukamia, but it can also be used to address various other illnesses like non-small cell lung cancer with local advancement, metastatic bladder cancer and lung cancers."
Has there been any previous research done on the combined use of LVGN3616, LVGN6051 and Nab-Paclitaxel?
"As of now, there are 420 Phase 3 trials and a total of 1868 studies concerning LVGN3616 + LVGN6051 + Nab-Paclitaxel. Most research sites can be found in Philadelphia, Pennsylvania; however, across the United States there are 76057 clinics researching this combination therapy."
What is the aggregate population of those participating in this medical experiment?
"That is correct. The clinicaltrials.gov web page reveals that recruitment for this research study, which was initially publicized on November 12th 2021, is continuing as planned. 352 individuals are required from a single medical institution to complete the trial."
Is this experiment still accepting participants?
"Affirmative. Clinicaltrials.gov displays that this large-scale trial, initially posted on November 12th 2021, is still open for enrollment and requires 352 individuals to be sourced from a single research site."
Share this study with friends
Copy Link
Messenger